You will be randomly assigned to one of two treatment groups. Both groups receive standard chemotherapy (FOLFOX or FOLFIRI) combined with either fruquintinib or bevacizumab.

Before starting treatment, you will complete a quality of life questionnaire (EORTC QLQ-C30).

If assigned to the fruquintinib group, you will receive hard capsules for oral use along with chemotherapy through intravenous infusion.

If assigned to the bevacizumab group, you will receive the medication through intravenous infusion along with chemotherapy.

Your physical condition will be assessed before each treatment cycle.

Your response to treatment will be evaluated through imaging scans at regular intervals.

Quality of life questionnaires will be completed every 2 months.

Side effects will be monitored and recorded for up to 30 days after the last treatment dose.

A major assessment will occur 4 months after starting treatment to evaluate how well the treatment is controlling the disease.

This evaluation will include imaging scans to measure tumor response.

Treatment will continue as long as it remains beneficial and tolerable.

Regular assessments will continue to monitor disease status and side effects.

Treatment may be adjusted or discontinued based on how your body responds.

After completing treatment, you will continue to be monitored for disease progression.

Follow-up visits will include health assessments and imaging scans.

Quality of life assessments will continue during this period.